Replies to post #64429 on Biotech Values

[DewDiligence]

MNTA ReadMeFirst

[Updated for 2Q08 financials
and disclosures from 2Q08 CC.]


What is MNTA’s business all about?
#msg-25513125 Quick primer by ThomasS
#msg-28919271 Morgan Stanley webcast (4/30/08)
#msg-28748329 MNTA helps FDA with contaminated heparin
#msg-30941510 2008-2009 news flow
#msg-25473104 Capsule explanation of proprietary technology
#msg-19626947 Sugars, peptides and glycoproteins, in that order
#msg-24624700 Apropos to above (2005 PR)
#msg-28865474 Characterizing a compound by “ruling out” structures
#msg-29053373 Odds and ends from 5/5/08 DB webcast


Valuation and finances
#msg-30936204 2Q08 financial results
#msg-29008722 Musings on valuation
#msg-30937598 Recent biotech buyouts at a large premium


Management and BoD
#msg-12824293 Craig Wheeler hired from Chiron
#msg-29957474 Composition of Board of Directors
#msg-29957568 Insider shareholdings
#msg-28899840 Largest shareholders
#msg-25377212 Standstill agreement with NVS expires 25-Jul-2008
#msg-27338039 James Roach appointed CMO


Generic-Lovenox program
#msg-29282120 Sanofi’s US Lovenox patent invalidated
#msg-30940416 Court to rule on rehearing (180-day clock)
#msg-28896384 MNTA to resubmit ANDA in 3Q08
#msg-12222305 2006 partnership with Sandoz
#msg-25534402 Economics of the Lovenox partnership (1)
#msg-29462063 Economics of the Lovenox partnership (2)
#msg-12685766 Royalties payable to MIT
#msg-28903176 Lovenox sells $4.5B per year
#msg-28934793 Largest-selling generic of all time?
#msg-28936334 Where do Lovenox sales come from?
#msg-26739674 Lovenox US market share
#msg-28900092 FDA action on Teva/Amphastar ANDA’s?
#msg-29728035 How generic Rx’s are written in Europe
#msg-29698599 Competition from new oral anticoagulants


M118 (proprietary anticoagulant) program
#msg-26897124 “Checklist” rationale for M118 program
#msg-29698599 M118 vs new oral anticoagulants
#msg-26900300 M118 has blockbuster potential
#msg-27272430 Meeting an unmet need
#msg-26898084 How M118 binds both FIIa and FXa (graphic)
#msg-26897732 M118 clinical trials
#msg-26809439 Rationale for lead indication in PCI
#msg-28193368 Phase-1 results presented at ASCPT


Generic-Copaxone program
#msg-30621490 FDA accepts Copaxone ANDA for review
#msg-30938608 MNTA/Sandoz have first-filer status
#msg-30649453 Notes from 7/11/08 Copaxone conference call
#msg-12222305 Copaxone falls under 2006 NVS collaboration
#msg-28903357 Copaxone sales keep growing
#msg-27177236 Copaxone has 25% worldwide share of MS market
#msg-26893858 Musings on upside of Copaxone program
#msg-30647865 “Controlled Chaos” (reverse engineering)
#msg-29593829 Musings on Teva’s US patents
#msg-29902618 Mylan enters the fray—sort of.
#msg-30498483 Teva’s trial with 40mg dose fails
#msg-29823176 NVS’ FTY720 hits a bump


Follow-on Biologics (FoB) programs
#msg-27114485 US FoB’s are a question of when not if
#msg-26837144 Salient FoB quote from MNTA’s CEO
#msg-12222305 2006 FoB partnership with Sandoz
#msg-25514154 Speculation on the FoB’s to be developed (ThomasS)


Competition
#msg-30498678 Existing and future anticoagulants
#msg-29698599 Competition from new oral anticoagulants


Feature stories on MNTA and related topics
#msg-27286206 Boston Globe (3/08)
#msg-25160571 WSJ (12/07)
#msg-25933221 Bioworld (11/07)
#msg-23005127 Nature (9/07)
#msg-20308884 Lab Technologist (6/07)
#msg-25803923 The Pink Sheet (3/07)
#msg-13119848 Chemical & Engineering News (9/06)
#msg-12686142 Boston Globe (8/06)
#msg-7370282 WSJ (8/05)
#msg-25779774 Boston Globe (11/04)